



News
VPM is now Serum Life Science Europe
We are thrilled to share an exciting update with you. After a period of thoughtful consideration, we are proud to announce that our company name, formerly Vakzine Projekt Management GmbH (VPM), has been changed to Serum Life Science Europe GmbH (SLS Europe).

News & Events
REGISTRATION IS OPEN!
It is our pleasure to announce that the 14th International VPM Days will take place on Thursday and Friday, 28 and 29 September 2023 at TWINCORE in Hannover, Germany.
NEWS
VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG
Press
Results of SAKK 06/14 trial with VPM1002BC
The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions.
A competent partner at your side
Free first consulting session
We understand how complexe product development is, because we did it ourselves. Let us be a competent partner at your side for a secure route to a successful product.
From Bench to Product
Consulting and services
A competent partner at your side
Free first consulting session
From Bench to Product
Consulting and services
Speed up your development processes by using our expertise. We offer a comprehensive service portfolio covering all stages of pharmaceutical development.
About Vakzine Projekt Management
VPM offers tailor-made consultancy and services based on in-depth experience in development of biopharmaceutical candidates. As a client, you will benefit from the experience of our team in translational project management. This enables you to bring your development projects into clinical trials faster, more cost-effectively and with a higher probability of success.
The company was established in 2002. Within the last decade, VPM has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs. VPM brought these products for its customers in the pharmaceutical industry, academic research and small biotechnology companies, from preclinical phase through clinical phases I-III.
News & Press
VPM is now Serum Life Science Europe
We are thrilled to share an exciting update with you. After a period of thoughtful consideration, we are proud to announce that our company name, formerly Vakzine Projekt Management GmbH (VPM), has been changed to Serum Life Science Europe GmbH (SLS Europe).

Stefan Kaufmann Advocates for Advancements in Tuberculosis Control
Renowned vaccine researcher, Prof. Dr. Stefan H. E. Kaufmann, recently shared his expertise and insights on tuberculosis in an exclusive interview with ETHealthworld. Prof. Dr. Kaufmann, the inventor of VPM1002, highlighted the urgent need for better TB vaccines and advancements in novel drug regimens to combat this global health challenge.Here is the link to his interview.
We are honored to introduce Prof. Dr. Kaufmann as the keynote lecturer at the 14th International VPM Days, taking place on September 28th and 29th at TWINCORE in Hannover. This event serves as a unique opportunity to learn from one of the foremost experts in the field and connect with like-minded professionals and researchers.
Register now via email to:VPMDays2023@vakzine-manager.de to secure your spot.
REGISTRATION IS OPEN!
It is our pleasure to announce that the 14th International VPM Days will take place on Thursday and Friday, 28 and 29 September 2023 at TWINCORE in Hannover, Germany. READ MORE






